Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country

Bibliographic Details
Main Author: Galvan, Cesar Alberto
Publication Date: 2020
Other Authors: Toribio-Dionicio, Crhistian Gabriel, Álvarez-Ángeles, Marco Antonio, Alama-Bazán, Óscar Daniel, Sánchez-Ramírez, Luis Alberto Antonio
Format: preprint
Language: spa
Source: SciELO Preprints
Download full: https://preprints.scielo.org/index.php/scielo/preprint/view/545
Summary: Currently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country.
id SCI-1_abc82abe7dbd3af2da2ebde5cf1a3d5c
oai_identifier_str oai:ops.preprints.scielo.org:preprint/545
network_acronym_str SCI-1
network_name_str SciELO Preprints
repository_id_str
spelling Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our countryTransfusión de plasma convaleciente de pacientes con COVID-19: Propuesta de la Sociedad Peruana de Inmunología y la Asociación Médica Peruana de Patología Clínica para su implementación en nuestro paísMERSPerúSARS-Cov-2SARSCOVID-19COVID-19MERSPeruConvalescent plasmaSARS-CoV-2SARS VirusCurrently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country.Actualmente no existe vacuna disponible ni medicación específica contra la enfermedad de Coronavirus 2019 (COVID-19). El tratamiento se basa fundamentalmente en medidas de soporte. En las últimas semanas, en varias partes del mundo, incluido nuestro país, se han dado flexibilidades para que la comunidad científica conduzca ensayos clínicos con terapias de potencial utilidad, como es el caso de la transfusión de plasma convaleciente (TPC) de pacientes con COVID-19. Se realizó una búsqueda en MEDLINE de estudios sobre plasma convaleciente y COVID-19, SARS o MERS. Los estudios sobre la eficacia clínica de este tratamiento en enfermedades causadas por otros coronavirus (SARS-CoV y MERS-CoV) evidenciaron mejoría clínica, aumento de anticuerpos neutralizantes, disminución de mortalidad y ausencia de eventos adversos durante y después del tratamiento. En el caso del COVID-19, se encontraron 6 estudios del uso de este tratamiento en pacientes con COVID-19 severo (en ventilación mecánica y con síndrome de distrés respiratorio agudo). Aunque existen limitaciones en la metodología, número de pacientes y protocolos para el análisis del plasma convaleciente de los donantes, los pacientes que recibieron TPC evidenciaron mejoría clínica, mejoría de patrones ventilatorios, resolución de lesiones pulmonares, disminución de mortalidad, mejoría de parámetros laboratoriales, aumento de anticuerpos neutralizantes, disminución de carga viral y ausencia de eventos adversos. Presentamos además un protocolo de realización de TPC y propuestas para su implementación y uso en nuestro país.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-26info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/54510.1590/SciELOPreprints.545spahttps://preprints.scielo.org/index.php/scielo/article/view/545/691Copyright (c) 2020 Cesar Alberto Galvan, Crhistian Gabriel Toribio-Dionicio, Marco Antonio Álvarez-Ángeles, Óscar Daniel Alama-Bazán, Luis Alberto Antonio Sánchez-Ramírezhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGalvan, Cesar AlbertoToribio-Dionicio, Crhistian GabrielÁlvarez-Ángeles, Marco AntonioAlama-Bazán, Óscar DanielSánchez-Ramírez, Luis Alberto Antonioreponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-22T01:59:20Zoai:ops.preprints.scielo.org:preprint/545Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-22T01:59:20SciELO Preprints - SciELOfalse
dc.title.none.fl_str_mv Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
Transfusión de plasma convaleciente de pacientes con COVID-19: Propuesta de la Sociedad Peruana de Inmunología y la Asociación Médica Peruana de Patología Clínica para su implementación en nuestro país
title Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
spellingShingle Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
Galvan, Cesar Alberto
MERS
Perú
SARS-Cov-2
SARS
COVID-19
COVID-19
MERS
Peru
Convalescent plasma
SARS-CoV-2
SARS Virus
title_short Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
title_full Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
title_fullStr Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
title_full_unstemmed Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
title_sort Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
author Galvan, Cesar Alberto
author_facet Galvan, Cesar Alberto
Toribio-Dionicio, Crhistian Gabriel
Álvarez-Ángeles, Marco Antonio
Alama-Bazán, Óscar Daniel
Sánchez-Ramírez, Luis Alberto Antonio
author_role author
author2 Toribio-Dionicio, Crhistian Gabriel
Álvarez-Ángeles, Marco Antonio
Alama-Bazán, Óscar Daniel
Sánchez-Ramírez, Luis Alberto Antonio
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Galvan, Cesar Alberto
Toribio-Dionicio, Crhistian Gabriel
Álvarez-Ángeles, Marco Antonio
Alama-Bazán, Óscar Daniel
Sánchez-Ramírez, Luis Alberto Antonio
dc.subject.por.fl_str_mv MERS
Perú
SARS-Cov-2
SARS
COVID-19
COVID-19
MERS
Peru
Convalescent plasma
SARS-CoV-2
SARS Virus
topic MERS
Perú
SARS-Cov-2
SARS
COVID-19
COVID-19
MERS
Peru
Convalescent plasma
SARS-CoV-2
SARS Virus
description Currently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country.
publishDate 2020
dc.date.none.fl_str_mv 2020-05-26
dc.type.driver.fl_str_mv info:eu-repo/semantics/preprint
info:eu-repo/semantics/publishedVersion
format preprint
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://preprints.scielo.org/index.php/scielo/preprint/view/545
10.1590/SciELOPreprints.545
url https://preprints.scielo.org/index.php/scielo/preprint/view/545
identifier_str_mv 10.1590/SciELOPreprints.545
dc.language.iso.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://preprints.scielo.org/index.php/scielo/article/view/545/691
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
dc.source.none.fl_str_mv reponame:SciELO Preprints
instname:SciELO
instacron:SCI
instname_str SciELO
instacron_str SCI
institution SCI
reponame_str SciELO Preprints
collection SciELO Preprints
repository.name.fl_str_mv SciELO Preprints - SciELO
repository.mail.fl_str_mv scielo.submission@scielo.org
_version_ 1797047817895673856